Fluvastatin with and without niacin for hypercholesterolemia

Jacobson, Terry A.; Chin, Margaret M.; Fromell, Gregg; Jokubaitis, Leonard; Amorosa, Louis F.

doi:10.1016/0002-9149(94)90088-4

Cited by 85 publications

(37 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jacobson et al [18]reported an increase in liver enzymes, while Olbricht and Koch [11]and Matzkies et al [10]reported satisfactory tolerance of statin in their nephrotic patients.…”

Section: Discussionmentioning

confidence: 99%

Impact of Treatment of Dyslipidemia on Renal Function, Fat Deposits and Scarring in Patients with Persistent Nephrotic Syndrome

Gheith

Sobh

Mohamed

et al. 2002

Nephron

View full text Add to dashboard Cite

In this study 43 patients with idiopathic nephrotic syndrome were randomly distributed into 2 age- and sex-matched groups. The first group was given fluvastatin while the second was used as control. The cases in the 2 groups were evaluated clinically, biochemically (creatinine clearance, albumin, 24-hour proteinuria, and lipogram), neurologically, and histopathologically (examination of renal biopsies obtained basally and after 1 year of treatment with fluvastatin). In the fluvastatin-treated group but not in the control group, we observed a significant reduction in cholesterol, low-density lipoprotein, and triglyceride. Clinical and laboratory assessment showed satisfactory tolerance of the drug by the patients. Proteinuria, serum albumin and creatinine clearance values were significantly better in the statin-treated patients. There was no difference in glomerular sclerosis between the 2 groups while interstitial fibrosis and renal fat deposits were less in the statin-treated group. The reduction in renal fat deposits in the statin-treated group was highly significant, while that of interstitial fibrosis was not. We conclude that: (1) statin can be safely and effectively used in the treatment of dyslipidemia in patients with persistent idiopathic nephrotic syndrome; (2) control of dyslipidemia in nephrotic patients is associated with better control of proteinuria and creatinine clearance; (3) statin treatment may cause regression of renal fat deposits in patients with nephrotic syndrome, and (4) longer term studies are still required to study further possible beneficial effects on renal histology and disease progression.

show abstract

“…Jacobson et al [18]reported an increase in liver enzymes, while Olbricht and Koch [11]and Matzkies et al [10]reported satisfactory tolerance of statin in their nephrotic patients.…”

Section: Discussionmentioning

confidence: 99%

Impact of Treatment of Dyslipidemia on Renal Function, Fat Deposits and Scarring in Patients with Persistent Nephrotic Syndrome

Gheith

Sobh

Mohamed

et al. 2002

Nephron

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that combinations of a statin plus either nicotinic acid 23 or gemfibrozil 24 provide additional benefits of reduced triglyceride levels, increased HDL-C, and improved LDL particle size; combination therapy has been shown to produce greater angiographic benefit than monotherapy. 25 Adding low-dose nicotinic acid (1 to 2 g/d) to a statin is particularly appealing because of the low cost and additional benefit of reducing Lp(a).…”

Section: Ballantyne Et Al February 16 1999mentioning

confidence: 99%

Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy

et al. 1999

View full text Add to dashboard Cite

Background —Patients with coronary artery disease (CAD) commonly have low HDL cholesterol (HDL-C) and mildly elevated LDL cholesterol (LDL-C), leading to uncertainty as to whether the appropriate goal of therapy should be lowering LDL-C or raising HDL-C. Methods and Results —Patients in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) had mildly to moderately elevated LDL-C; many also had low HDL-C, providing an opportunity to compare angiographic progression and the benefits of the HMG-CoA reductase inhibitor fluvastatin in patients with low versus patients with higher HDL-C. Of the 339 patients with biochemical and angiographic data, 68 had baseline HDL-C <0.91 mmol/L (35 mg/dL), mean 0.82±0.06 mmol/L (31.7±2.2 mg/dL), versus 1.23±0.29 mmol/L (47.4±11.2 mg/dL) in patients with baseline HDL-C ≥0.91 mmol/L. Among patients on placebo, those with low HDL-C had significantly more angiographic progression than those with higher HDL-C. Fluvastatin significantly reduced progression among low–HDL-C patients: 0.065±0.036 mm versus 0.274±0.045 mm in placebo patients ( P =0.0004); respective minimum lumen diameter decreases among higher–HDL-C patients were 0.036±0.021 mm and 0.083±0.019 mm ( P =0.09). The treatment effect of fluvastatin on minimum lumen diameter change was significantly greater among low–HDL-C patients than among higher–HDL-C patients ( P =0.01); among low–HDL-C patients, fluvastatin patients had improved event-free survival compared with placebo patients. Conclusions —Although the predominant lipid-modifying effect of fluvastatin is to decrease LDL-C, patients with low HDL-C received the greatest angiographic and clinical benefit.

show abstract

“…Short and medium term effects on reducing serum lipoprotein(a) have been reported using niacin (17), tamoxifen (18) and plant extracts (19) and in non-treated hyperthyroidism (20). Hydroxymethylglutaryl-CoA reductase inhibitors (17) and fibrous diets (21), although efficient in reducing LDL-cholesterol levels, do not significantly alter lipoprotein(a) concentrations, again highlighting the different metabolic pathway of the latter.…”

Section: Discussionmentioning

confidence: 99%

Lipoprotein(a) Concentrations in Non-Selected Hospitalised Patients Between 18 and 100 Years of Age: Comparison with Cholesterol Fractions and Triacylglycerols in Patients with Lipid Status Requests

Wood¹,

Schumacher²

1995

CCLM

View full text Add to dashboard Cite

Summary:In a study designed to measure lipoprotein(a), cholesterol, cholesterol fractions and triacylglycerols in serum 4004 hospitalised individuals aged between 18 and 100 years were examined. Lipoprotein(a) was determined in 1313 patients (438 males, 875 females) aged 18-59 years and 489 patients (234 males, 255 females) aged 60-100 years. Cholesterol, cholesterol fractions and triacylglycerols were determined in a further 2037 patients (1084 males, 953 females) aged 18 to 100 years, for whom a lipid-status request had been made. Lipoprotein(a) concentrations in 619 females measured directly postpartum were not significantly different from aged-matched female in-patients (n = 104) and age-matched female hospital staff (n = 114). Lipoprotein(a) concentrations in women (n = 77) aged 30-74 undergoing chronic haemodialysis were significantly higher (p < 0.001) than in men (n = 95) of the corresponding age group. Median lipoprotein(a) serum concentrations showed a peak between 60-69 years in both men and women, i. e. at times of reported increased cardiovascular disease in both sexes. The lipoprotein(a) levels found in old age are comparable with those found in children and adolescents. The lipoprotein(a) patient group was assessed according to age and clinic. Eight groups of patients were analysed. The maternity patients were significantly younger (median age 26 a) than the other seven groups (p < 0.05-< 0.01), the hospital employees (median age 31 a) attending the annual check-up being younger than the remaining six groups (p < 0.01). Lipoprotein(a) concentrations were marginally higher (p = 0.05) in the dialysis patients, when compared with those on internal medical wards. Of the 'traditional' lipid analytes, the ratio LDL-cholesterol : HDL-cholesterol was of interest, being significantly higher in males aged 70-79 years of age, when compared with males under 30 years of age. Triacylglycerols were higher in men aged between 30 and 59 years (p = 0.05-< 0.01). The relationship between median analyte concentration and age was different for lipoprotein(a) than for the ratio LDL-cholesterol : HDL-cholesterol and triacylglycerols, thus further supporting the fact that lipoprotein(a) may be an independent risk factor for the development of atherosclerotic disease.

show abstract

Fluvastatin with and without niacin for hypercholesterolemia

Cited by 85 publications

References 16 publications

Impact of Treatment of Dyslipidemia on Renal Function, Fat Deposits and Scarring in Patients with Persistent Nephrotic Syndrome

Impact of Treatment of Dyslipidemia on Renal Function, Fat Deposits and Scarring in Patients with Persistent Nephrotic Syndrome

Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy

Lipoprotein(a) Concentrations in Non-Selected Hospitalised Patients Between 18 and 100 Years of Age: Comparison with Cholesterol Fractions and Triacylglycerols in Patients with Lipid Status Requests

Contact Info

Product

Resources

About